semaglutide bmi md reviews GLP-1 for Medical Weight Loss A Review of the Oral
Description
Common AEs were nausea (23%), vomiting (6%), diarrhea (6%), constipation (10%), headache (6%), fatigue (8%), abdominal pain (2%), and abdominal bloating (2%)
Clinicians should exercise caution in individuals with predisposing ocular risk factors, such as small Bruchs membrane opening (BMO), optic disc drusen (ODD), or otherwise crowded optic nerve heads
The increased use of GLP-1 receptor agonists, particularly for the treatment of obesity, has been well documented
In addition, WHO included GLP-1 therapies on its Essential Medicines List (EML)
